Research Article

Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

Table 1

Baseline characteristics in patients with fulminant colitis treated with infliximab in an opened randomized controlled open-label study.

ActiveControl 𝑃

Age47 (29–66)27 (15–76) . 0 4 3
Sex (M/F)8/510/3Ns
Tobacco (yes/no)0/132/11Ns
Duration of disease (years)1 (0–19)0.5 (0–10)Ns
Localization of disease2/4/71/3/9Ns
Proctus/left colon/total
UCDAI score12 (12-12)12 (12-12)Ns
Treatment at inclusion
 5-ASA ( y e s / n o ) 7 / 6 4 / 9 Ns
 Immunosuppressive ( y e s / n o ) 0 / 1 3 1 / 1 2 Ns
 Biochemistry
 Hemoglobin (g/dL)11.7 (6.8–16.1)12.7 (9.3–14.1)Ns
 Albumin (g/L)32.6 (22.1–43.9)32.9 (23.4–38.4)Ns
 CRP (mg/L)59 (6–263)72 (7–316)Ns
 ESR (mm/h)41 (15–97)32 (14–65)Ns

Continuous variables are median (min-max). Asterisk: Mann-Whitney; Pearson Chi Square or Fishers Exact Test as appropriate.